Intracellular uptake of EGCG-loaded deformable controlled release liposomes for skin cancer. (2nd April 2020)

• Record Type: Journal Article
• Authors: Marwah, M.; Perrie, Y.; Badhan, R. K. S.; Lowry, D.
• Is Part Of: Journal of liposome research. Volume 30:Number 2(2020)
• Page Start: 136
• Page End: 149
• Publication Date: 2020-04-02
• Subjects: Skin cancer -- deformable liposomes -- dermal release -- controlled release -- elastic liposomes; Liposomes -- Periodicals; Liposomes -- Periodicals; 575.57
• DOI: 10.1080/08982104.2019.1604746
• Languages: English
• ISSNs: 0898-2104

Abstract

Abstract: Caucasian population groups have a higher propensity to develop skin cancer, and associated clinical interventions often present substantial financial burden on healthcare services. Conventional treatments are often not suitable for all patient groups as a result of poor efficacy and toxicity profiles. The primary objective of this study was to develop a deformable liposomal formulation, the properties of which being dictated by the surfactant Tween 20, for the dermal cellular delivery of epigallocatechin gallatein (EGCG), a compound possessing antineoplastic properties. The results demonstrated a significant ( p ≤ 0.05) decrease in liposome deformability index (74 ± 8 to 37 ± 7) as Tween 20 loading increased from 0 to 10% w/w, indicating an increase in elasticity. EGCG release over 24-h demonstrated Tween 20 incorporation directly increased release from 13.7% ± 1.1% to 94.4% ± 4.9% (for 0 and 10% w/w Tween 20 respectively). Finally, we demonstrated DilC-loaded deformable liposomes were localized intracellularly within human dermal fibroblast and keratinocyte cells within 2 h. Thus, it was evident that deformable liposomes may aid drug penetration into dermal cells and would be useful in developing a controlled-release formulation.